Objective:To investigate the value of multislice spiral computed tomography (MSCT) features in the differential diagnosis of pancreatic solid pseudopapillary neoplasm (pSPN) and hypovascular pancreatic neuroendocrine tumor (hypo-PNET).Methods:From January 2016 to January 2021, at Zhongshan Hospital of Fudan University, the clinical information, pathological results and imaging data of 81 patients with pSPN and 40 patients with hypo-PNET confirmed by surgical pathology were retrospectively analyzed. The tumor location, shape, growth mode, relationship between the long axis of the lesion and pancreas, boundary, whether with calcification, floating cloud sign, ring enhancement, sausage-like enhancement, intratumoral vascular sign, pancreatic duct dilatation, distal pancreatic atrophy, intratumoral cystic change, cystic-solid ratio of tumor, the maximum diameter of the lesion, the plain and enhanced computed tomography (CT) values of the solid part of the tumor of pSPN patients and hypo-PNET patients were compared and analyzed. Chi-square test, independent sample t test and Mann-Whitney U test were used for statistical analysis. The variables with statistical significance in univariate analysis were included in the binary logistic regression model to screen the independent predictors of pSPN and hypo-PNET, and the receiver operating characteristic curve (ROC) was used to evaluate the diagnostic efficiency of MSCT characteristics in the differential diagnosis of pSPN and hypo-PNET. Results:Compared with hypo-PNET patients, most of pSPN patients were female (71.6%, 58/81 vs. 45.0%, 18/40), younger (36.0 years old (27.0 years old, 46.0 years old) vs. 56.5 years old (48.2 years old, 63.7 years old), the tumors were mostly round or elliptical (76.5%, 62/81 vs. 55.0%, 22/40), most with clear boundaries (70.4%, 57/81 vs. 40.0%, 16/40), with more intratumoral calcification (53.1%, 43/81 vs. 20.0%, 8/40), with more floating cloud sign (65.4%, 53/81 vs. 35.0%, 14/40), more without intratumoral vascular sign (77.8%, 63/81 vs. 32.5%, 13/40), more without pancreatic duct dilatation (79.0%, 64/81 vs. 55.0%, 22/40), more with mixed solid and cystic mass (38.3%, 31/81 vs. 22.5%, 9/40), with longer maximum diameter of tumor (4.0 cm (3.0 cm, 5.6 cm) vs. 3.3 cm (2.6 cm, 4.2 cm), with lower enhanced CT values in the arterial and venous phases ((54.7±13.1) HU vs. (68.2±15.0) HU and (65.9±16.0) HU vs. (79.2±14.2) HU), and the differences were all statistically significant ( χ2=8.11; Z=-6.24; χ2=5.85, 10.32, 12.02, 10.03, 23.50, 7.51, 7.72; Z=-2.53; t=-5.08 and -4.46, all P<0.05). The results of binary logistic regression model indicated that the independent predictive factors for the diagnosis of pSPN and hypo-PNET included age ( OR=0.874, 95% confidence interval (95% CI) 0.827 to 0.923, P<0.001), calcification ( OR=5.412, 95% CI 1.428 to 20.506, P=0.013), intratumoral vascular sign ( OR=0.212, 95% CI 0.055 to 0.817, P=0.024), CT value in the arterial phase ( OR=0.943, 95% CI 0.899 to 0.988, P=0.015). For the combination diagnostic model based on clinical features and MSCT characteristics, area under ROC was 0.944 (95% CI 0.905 to 0.990), sensitivity was 87.7% and specificity was 92.5% ( P<0.001). The results of ROC analysis of the independent predictive factors and combined diagnostic model showed that the areas under the curve (95% CI) of the age, calcification, intratumoral vascular sign, CT value in the arterial phase and the combined diagnostic model was 0.665 (0.565 to 0.765), 0.726 (0.627 to 0.826), 0.850 (0.775 to 0.924), 0.757 (0.660 to 0.853), and 0.944 (0.905 to 0.983), respectively, and the diagnostic efficacy of the combined diagnostic model was higher ( P<0.001). Conclusion:MSCT features such as intratumoral calcification, intratumoral vascular sign, tumor density in the arterial phase combined with age can be used in the differential diagnosis of pSPN and hypo-PNET.

Objective:To observe the clinical effect of Shenfu injection in preventing septic cardiomyopathy (SIC) in septic patients.Methods:From June 2022 to January 2023, patients with sepsis or septic shock who did not develop SIC were randomly divided into treatment group and control group according to the ratio of 1:1. In the treatment group, Shenfu injection (50 mL) was pumped intravenously once every 12 hours for 5 days. In the control group, 50 mL of normal saline was pumped intravenously once every 12 hours, and the course of treatment was 5 days. The primary end point was the incidence of SIC in the first 5 days. The secondary end points were the application time of vasoactive drugs, fluid balance in the previous week, hospitalization time in ICU, total ventilation time and 28-day mortality.Results:112 patients were randomly divided into two groups. Seven patients in the treatment group were excluded twice, and finally 49 patients were included in the analysis, while six patients in the control group were excluded twice and 50 patients included in the analysis. The total incidence of SIC in the treatment group within 5 days was significantly lower than that in the control group (42.9% vs. 64.0%, P = 0.035). Among them, the left ventricular systolic dysfunction in the treatment group was significantly lower than that in the control group (24.5% vs 52.0%, P=0.005), and there was no significant difference in the incidence of left ventricular diastolic dysfunction between the two groups. The incidence of right ventricular dysfunction in the control group was 28.0%, which was significantly higher than 10.2% in the treatment group ( P = 0.025). The duration of using vasoconstrictors in the treatment group was 75(48, 97) hours, which was significantly lower than 97(66, 28) hours in the control group ( P = 0.039). The duration of inotropic drugs use in the treatment group was 32(18, 49) h, which was also significantly shorter than 44(25, 61) h in the control group ( P=0.046). The fluid balance of the control group in the first week was (1 260±850) mL, which was significantly higher than (450±520) mL in the treatment group ( P=0.008). There was no statistical difference in ICU stay, total ventilation time and 28-day mortality between the two groups (all P > 0.05). Conclusion:Early application of Shenfu injection can significantly reduce the incidence of SIC, accompanied by less use of vasoactive drugs and positive fluid balance, which has a good clinical application prospect.